▲ 8 r/HUMACYTE
Don't get it, if that is the price reaction on positive Phase 3 data with planned sBLA submission to follow, how would the market react if the data was failure?
I know that biotech stocks are volatile as hell with heavy swings, but they mostly climb higher on positive trial data, and Humacyte proved that now for the 2nd time, and now targeting much larger TAM than trauma
Can someone give me logical answer to what's happening? Wasn't that supposed to be the highest catalyst in the history of this company?
u/a_human_21 — 12 days ago